Erythropoietn; A rare culprit of anemia in chronic kidney disease
Open Access
|Jun 2021Abstract
Erythropoietin-induced antibody-mediated pure red cell aplasia is a rare and unexpected devastating adverse effect of erythropoietin analog. Patient and product-related factors, along with factors related to storage, determine the immunogenicity of erythropoietin. Early identification and withdrawal of erythropoietin with immunosuppressive therapy would improve the outcome. Here we present a 69-year-old male with chronic kidney disease treated with erythropoietin, had refractory anemia due to antibody-mediated pure redcell aplasia.
DOI: https://doi.org/10.4038/jpgim.8319 | Journal eISSN: 2362-0323
Language: English
Published on: Jun 30, 2021
Published by: Postgraduate Institute of Medicine University of Colombo
In partnership with: Paradigm Publishing Services
Keywords:
© 2021 Piratheepan Navaradnam, Thirunavukarasu Kumanan, Thaneshwary Sooriyakumar, published by Postgraduate Institute of Medicine University of Colombo
This work is licensed under the Creative Commons License.